Aptinyx Temettü

Temettü kriter kontrolleri 0/6

Aptinyx şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Ödeme oranı

Sektör ortalama getirisi	2.2%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Hisse başına kazanç	-US$0.98
Gelecekteki Temettü Verimi	n/a

Son temettü güncellemeleri

Recent updates

What Kind Of Shareholders Hold The Majority In Aptinyx Inc.'s (NASDAQ:APTX) Shares?

Jan 30

Aptinyx recommences Phase 2 study of NYX-2925

Jan 04

Have Insiders Been Buying Aptinyx Inc. (NASDAQ:APTX) Shares This Year?

Dec 26

What Type Of Returns Would Aptinyx's(NASDAQ:APTX) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Nov 27

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: APTX şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: APTX şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Aptinyx Piyasaya Karşı Temettü Getirisi

APTX temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (APTX)	n/a
Pazarın Alt %25'i (US)	1.5%
Pazarın En İyi %25'i (US)	4.6%
Sektör Ortalaması (Biotechs)	2.2%
Analist tahmini (APTX) (3 yıla kadar)	n/a

Önemli Temettü: APTX şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, APTX şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: APTX şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: APTX herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Aptinyx Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Aptinyx Inc. Approves Liquidating Cash Distribution

Recent updates

Aptinyx Inc. Approves Liquidating Cash Distribution

Nasdaq to Delist the Common Stock of Aptinyx

Aptinyx Inc. Announces Chief Executive Officer Changes

Aptinyx Inc. is Heading Towards Bankruptcy

Aptinyx Inc. announced delayed 10-Q filing

The Nasdaq Stock Market LLC Notifies Aptinyx Regarding Non-Compliance with Certain Board and Committee Composition Listing Requirements

Aptinyx Inc. Announces Executive Changes

Aptinyx Receives Non-Compliance Notice from Nasdaq

Aptinyx Inc. Announces Resignation of Patrick Enright from Board of Directors

Price target decreased to US$2.27

High number of new directors

Aptinyx Inc. to Report Q3, 2022 Results on Nov 08, 2022

Aptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson’s Disease and Dementia with Lewy Bodies

Aptinyx Inc. Reports Results from Phase 2b Study of NYX-2925 in Fibromyalgia

Aptinyx musculoskeletal pain drug NYX-2925 fails mid-stage study

Aptinyx Inc. Announces Poster Presentation Highlighting Preclinical Data on NYX-783 in Models of PTSD At the 2022 American Psychiatric Association Annual Meeting

Price target decreased to US$5.33

Aptinyx Inc. Presents Preclinical Data on NYX-783 in Models of PTSD at 2022 Society of Biological Psychiatry Annual Meeting

High number of new directors

Price target decreased to US$6.50

Aptinyx Inc. Announces Publication in Molecular Psychiatry Demonstrating Reduction of Spontaneous Recovery of Fear with Nyx-783

Aptinyx Inc Announces Temporarily Paused the Initiation of its Phase 2b Study of the 150 mg Dose of NYX-783 in Patients with Post-Traumatic Stress Disorder

Aptinyx Inc., Annual General Meeting, May 26, 2022

Price target decreased to US$7.71

Aptinyx Inc. Reports Results from Phase 2B Study of Nyx-2925 in Painful Diabetic Peripheral Neuropathy

Consensus forecasts updated

Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Fibromyalgia

Aptinyx Inc. Announces Formation of Scientific Advisory Board

High number of new directors

Independent Director recently bought US$50k worth of stock

Aptinyx Initiates Phase 2B Study of NYX-783 in Patients with Post-Traumatic Stress Disorder

CFO & Chief Business Officer recently bought US$102k worth of stock

Independent Director recently bought US$192k worth of stock

Third quarter 2021 earnings released: US$0.31 loss per share (vs US$0.24 loss in 3Q 2020)

High number of new directors

We're Keeping An Eye On Aptinyx's (NASDAQ:APTX) Cash Burn Rate

Consensus forecasts updated

Aptinyx: CNS Drug Discoverer With Depressed Price

Aptinyx Inc.(NasdaqGS:APTX) dropped from Russell 3000E Value Index

Aptinyx Inc. Provides Update on NYX-783 Development Program for the Treatment of Post-Traumatic Stress Disorder

Aptinyx updates on mid-stage clinical program for PTSD therapy

First quarter 2021 earnings released: US$0.21 loss per share (vs US$0.34 loss in 1Q 2020)

Aptinyx Inc. Presents Additional Positive Data from Phase 2 Exploratory Study of NYX-783 in PTSD At Society of Biological Psychiatry Annual Meeting

Aptinyx (NASDAQ:APTX) Is In A Good Position To Deliver On Growth Plans

Full year 2020 earnings released: US$1.02 loss per share (vs US$1.71 loss in FY 2019)

Did You Miss Aptinyx's (NASDAQ:APTX) 15% Share Price Gain?

New 90-day low: US$3.20

Aptinyx Inc. to Report Q4, 2020 Results on Mar 24, 2021

What Kind Of Shareholders Hold The Majority In Aptinyx Inc.'s (NASDAQ:APTX) Shares?

New 90-day high: US$4.33

Aptinyx Announces Recommencement of Phase 2 Study of NYX-2925 in Patients with Painful Diabetic Peripheral Neuropathy

Aptinyx recommences Phase 2 study of NYX-2925

Aptinyx Appoints Andy Kidd as President and COO

Have Insiders Been Buying Aptinyx Inc. (NASDAQ:APTX) Shares This Year?

Aptinyx Inc. Appoints Andy Kidd, M.D. as President and Chief Operating Officer

What Type Of Returns Would Aptinyx's(NASDAQ:APTX) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Analysts update estimates

Analysts update estimates

Price target lowered to US$10.50

Aptinyx Inc. to Report Q3, 2020 Results on Nov 12, 2020

New 90-day low: US$2.98

Aptinyx Reports Positive, Statistically Significant, Top-Line Data from Phase 2 Study of Nyx-783 in Patients with Post-Traumatic Stress Disorder

Aptinyx Inc. Recommences Patient Recruitment in Phase 2 Study of NYX-2925 in Patients with Fibromyalgia

New 90-day low - US$3.48

Analysts update estimates

First half earnings released

Aptinyx Inc. to Report Q2, 2020 Results on Aug 13, 2020

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin